<DOC>
	<DOCNO>NCT00701714</DOCNO>
	<brief_summary>This randomize , control , double-blind , multicenter multinational safety study involve 300 predialysis patient age 18 year suffer anemia . Symptomatic anemia correct s.c. application EPO HEXAL ERYPO® order achieve hemoglobin target range 10.0 -12.0 g/dL .</brief_summary>
	<brief_title>Randomized , Controlled , Double-blind Multicenter Safety Study Evaluate Safety Immunogenicity Subcutaneous EPO HEXAL vs. ERYPO® Treatment Anemia Associated With Chronic Renal Insufficiency Predialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Known chronic renal insufficiency least 4 week duration ; CKD stage least 3 high Male female patient , age : &gt; =18 Patients naïve ESA treatment previously ESA treat 3 month ESAfree period ( i.v . s.c. ) Patients symptomatic anemia , define Hb level 11.0 g/dL low equal 7.5 g/dL least 2 visit screen period Adequate iron status , serum ferritin &gt; = 100 µg/L transferrin saturation &gt; = 20 % Ability follow study instruction likely complete require visit compliant subcutaneous administration Written inform consent patient . Anemia nonrenal cause Therapy immunosuppressant ( corticosteroid chronic treatment ) within 3 month screen study patient renal allograft place chronic condition ( e.g . lupus erythematosus , rheumatic arthritis ) Patients previously treat chronic dialysis within last 6 month ( exception : one session acute dialysis ) Patients acute deterioration renal function screen phase accord investigator 's judgment Patients receive RBC/whole blood transfusion screen period Primary hematological disorder ( e.g . myeloma , myelodysplastic syndrome , sickle cell anemia , hematological malignancy , hemolytic anemia ) Evidence uncontrolled diabetes mellitus ( HbA1c &gt; 10 % visit 2 ) Evidence severe hepatic dysfunction ( e.g . ALT and/or AST 2x upper limit normal range ; gammaGT 3x upper limit normal range ) Clinical evidence current uncontrolled symptomatic hyperparathyroidism , define parathyroid hormone &gt; 500 ng/L visit 2 . Uncontrolled hypertension , define systolic blood pressure &gt; = 160 mmHg diastolic blood pressure measurement &gt; = 100 mmHg ( average two value least one day measurement ) Congestive heart failure and/or angina pectoris [ New York Heart Association ( NYHA ) class III IV ] History stroke myocardial infarction last 6 month prior visit 2 Ongoing treatment phenprocoumon cumarin derivates Thrombocytopenia ( platelet count &lt; 100.000/µL ) leucopenia ( white blood cell count &lt; 2.000/µL ) Gastrointestinal bleeding within last 6 month prior visit 2 hemolysis Evidence acute chronic infection Creactive protein value &gt; 30 mg/L Suspicion know PRCA ( pure red cell aplasia ) Previously diagnose HIV acute hepatitis infection History epilepsy epileptic seizure treatment epilepsy within past 6 month prior screen Planned major surgery ( expect high blood loss ) next 3 month major surgery within previous 3 month ( except laser photocoagulation , access surgery ) Clinical evidence active malignant disease within last 5 year ( except nonmelanoma skin cancer ) Pregnancy , breastfeed woman woman use highly effective birth control method ( e.g . implant , injectables , combine oral contraceptive , IUD , sexual abstinence , vasectomised partner ) Known history severe drug relate allergy ( e.g . anaphylactic shock ) Known allergy one ingredient test product hypersensitivity mammalianderived product Known suspicion noncompliance respect subcutaneous treatment Simultaneous participation another clinical study participation study month precede visit2 previously randomize study Participation another ESA study 3 month precede visit 2 Any condition investigator 's discretion may put patient risk may confound study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Treatment</keyword>
	<keyword>associate</keyword>
	<keyword>CRI</keyword>
</DOC>